

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

KUZYK LAW, LLP
Michael D. Braun (SBN 167416)
mdb@kuzykclassactions.com
1999 Avenue of the Stars, Ste. 1100
Los Angeles, CA 90067
Telephone: (213) 401-4100
Facsimile: (213) 401-0311

Counsel for Plaintiff

**UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
OAKLAND DIVISION**

**ALFREDO HERNANDEZ on behalf of
himself and all others similarly situated,**

Plaintiff,

v.

MIMI'S ROCK, CORP.

Defendant

CASE NO.:

CLASS ACTION

**COMPLAINT FOR DAMAGES,
EQUITABLE, DECLARATORY, AND
INJUNCTIVE RELIEF**

DEMAND FOR JURY TRIAL

1 Plaintiff Alfredo Hernandez (“Plaintiff”), on behalf of himself and all others similarly
2 situated, brings this class action against Mimi’s Rock Corp. (“MRC” or “Defendant”), and on the
3 basis of personal knowledge, information and belief, and the investigation of counsel, alleges as
4 follows:

5
6 **INTRODUCTION**

7 1. This is a proposed class action on behalf of a nationwide and California class of
8 consumers seeking redress for Defendant’s deceptive practices associated with the advertising,
9 labeling and sale of its Dr. Tobias Omega 3 Fish Oil Triple Strength dietary supplement (“Product”
10 or “Supplement”).

11 2. Fish is a major source of healthful long-chain omega-3 fats and are rich in other
12 nutrients, high in protein, and low in saturated fat. Numerous studies have shown that consuming
13 fatty fish 2-3 times a week may reduce the risk of heart disease and stroke, as well as provides a
14 myriad of additional health benefits. Scientific consensus affirms that consuming fatty fish as part of
15 a diet materially contributes to good health.

16 3. Unfortunately, most Americans do not, or cannot, consume fatty fish with such
17 regularity, and have instead turned to the consumption of fish oil to supplement their diets.

18 4. Indeed, as of 2012, fish oil supplements had become the most commonly used non-
19 vitamin, non-mineral dietary supplement sold in the U.S., and to this day remain one of the most
20 popular dietary supplement offerings. In 2019, the global fish oil market was valued at \$1.9 billion,
21 and is currently estimated to reach \$2.8 billion by 2027. It remains a lucrative business with
22 numerous market participants vying for consumer attention and their spending dollars.

23 5. Defendant manufactures, labels and sells a Product which it claims to be a Triple
24 Strength Fish Oil containing of 2,000 mg of Fish Oil including 800 mg of Eicosapentaenoic Acid
25 (“EPA”) and 600 mg of Docosahexaenoic Acid (“DHA”) – the essential omega-3 fatty acids that
26 naturally occur in fish.



6. Contrary to what is represented on the label, however, this Product is not fish oil, nor does it contain a single milligram of EPA or DHA. What was once natural fish oil has been subjected to a chemical process by which its molecular structure and constituent parts have been substantially transformed and irrevocably altered into a synthesized product that does not otherwise exist in nature. Through a chemical process known as trans-esterification, ethanol, an industrial solvent, is introduced into fish oil and combined with catalyst to break the natural triglyceride bonds and cleave the glycerol backbone from the fatty acid molecules. Fish oil is stripped of hundreds of its constituent sub ingredients, and the Omega-3s, which include DHA and EPA, are converted into ethyl esters of fatty acids. Critically, these newly formed ethyl esters of fatty acids are different molecules than the Omega-3s which exist naturally in fish oil. The new chemical by-products are universally recognized by their common or usual name -- Omega-3 Fatty Acid Ethyl Esters.

GENERAL ALLEGATIONS

A. OMEGA-3 FATTY ACIDS

22. Omega-3 Fatty Acids (“Omega-3” or “OM3”) are polyunsaturated carboxylic acids that provide numerous health benefits to the human body including a variety of critical organs and systems (e.g., heart, brain, eyes, blood vessels, lungs, immune, endocrine, and reproductive systems).²

23. Among the 11 types of OM3s, the three most important to human physiology are alpha-linolenic acid (“ALA”), docosahexaenoic acid (“DHA”) and eicosapentaenoic acid (“EPA”).³

24. ALA Omega-3 fatty acids are primarily found in plant oils and generally used by the human body for energy. To be used for something other than energy, ALA must first be converted into EPA or DHA. Unfortunately, this conversion process is inefficient and results in only a small percentage of ALA being converted into EPA and DHA.

25. In contrast, the primary source of EPA and DHA are marine oils from fatty fish and other seafoods.

26. Although experts have not established a daily recommended amount for DHA and EPA, the National Institutes of Health, Office of Dietary Supplements (“NIH”) acknowledges that many scientific studies show that eating fatty fish rich in DHA and EPA has beneficial effects with respect to a variety of adverse health conditions such as cardiovascular disease, age-related macular

² *Omega-3 Fatty Acids*, National Institutes of Health, Office of Dietary Supplements, available at <https://ods.od.nih.gov/factsheets/Omega3FattyAcids-Consumer>; H. Breivik, *Long-chain Omega-3 Specialty Oils*, Woodhead Publishing in Food Science, Technology and Nutrition at 11 (hereinafter “Breivik at ___”)(Clinical research has suggested that Omega-3s help prevent cardiovascular disease, Alzheimer’s, dementia, macular degeneration, and rheumatoid arthritis. There is also support that Omega-3s provide benefits for sufferers of arthritis, Crohn’s disease and patients with neuropsychiatric disorders such as depression and schizophrenia).

³ Other Omega-3s include: hexadecatrienoic acid (HTA); stearidonic acid (SDA); eicosatrienoic acid (ETE); eicosatetraenoic acid (ETA); heneicosapentaenoic acid (HPA); docosapentaenoic acid (DPA); tetracosapentaenoic acid; and tetracosahexaenoic acid.

1 degeneration, Alzheimer’s disease, dementia, dwindling cognitive function, rheumatoid arthritis,
2 high blood pressure, and variety of other conditions including certain cancers.⁴

3 27. Between 2017 and 2019, the American Heart Association (“AHA”) released three
4 science advisories related to Omega-3s, all of which recommend adults consume one to two servings
5 of seafood per week to reduce the risk of congestive heart failure, coronary artery disease, stroke,
6 and sudden cardiac death. For people with existing coronary artery disease, the AHA recommends
7 approximately 1g/day of EPA plus DHA, preferably from oily fish.⁵

8 28. In 2019 the U.S. Food and Drug Administration (“FDA”) considered the weight of
9 scientific evidence on the impact of OM3s and approved five qualified health claims relating to the
10 consumption of the EPA/DHA and its effect on heart health.⁶

11 29. Unfortunately, Americans generally do not consume a sufficient amount of fatty fish
12 necessary to maintain adequate levels of EPA and DHA. In response to this deficiency, health care
13 professionals began recommending that Americans supplement their diets with fish oil.⁷

14 30. In 1995, fish oil supplements generated only \$35 million in annual sales. By 2005,
15 that number had increased to \$310 million, and by 2012 fish oil supplements had become the non-
16 vitamin/non-mineral natural product most commonly taken by both adults and children with

17 _____
18 ⁴ Available at <https://ods.od.nih.gov/factsheets/Omega3FattyAcids-Consumer/>

19 ⁵ Etherton, P., et al, *Omega-3 Fatty Acids and Cardiovascular Disease New Recommendations From*
20 *the American Heart Association*, AHA Arteriosclerosis, Thrombosis, and Vascular Biology Journal
(2003) available at <https://www.ahajournals.org/doi/full/10.1161/01.ATV.0000057393.97337.AE>;
21 *See also*, National Institutes of Health, *Omega-3 Fatty Acids*, available at
22 <https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/#:~:text=For%20people%20with%20existing%20coronary,of%20a%20physician%20%5B80%5D>.

23 ⁶ *FDA Announces New Qualified Health Claims for EPA and DHA Omega-3 Consumption and the*
24 *Risk of Hypertension and Coronary Heart Disease*, June 19, 2019, available at
25 <https://www.fda.gov/food/cfsan-constituent-updates/fda-announces-new-qualified-health-claims-epa-and-dha-omega-3-consumption-and-risk-hypertension-and>.

26 ⁷ Mackay, *A Comparison of Synthetic Ethyl Ester Form Fish Oil vs. Natural Triglyceride Form*,
27 available from
28 <http://www.promedics.ca/site/downloads/Triglycerides%20vs%20Ethyl%20Esters.pdf>.

1 approximately 7.8 percent of adults (18.8 million) and 1.1 percent of children age 4 to 17 (664,000)
 2 regularly consuming fish oil supplements.⁸ By 2019, the global fish oil market had grown to \$1.9
 3 billion, and is currently estimated to reach \$2.8 billion by 2027.⁹

4 **B. FISH OIL**

5
 6 31. Omega-3 fatty acids, including EPA and DHA, are found in a variety of fatty fish
 7 such menhaden, sardines, anchovies, salmon and tuna.¹⁰ The oil from these fish is extracted by a
 8 fairly straightforward process which has been employed in a similar fashion since the early 1800s
 9 whereby fish were caught, cooked and a rock weighted process used to press oil from them.¹¹

10 32. Today, the process remains relatively the same. Once fish are caught, they are on-
 11 boarded to a fishing vessel and quickly boiled. The fish are cooked and pressed, separating the water
 12 and oil from proteins and solids. Thereafter, the water is separated from the oil. The oil undergoes a
 13 polishing process (i.e., deacidifying, degumming, and washing the oil several times). It is


14
 15
 16
 17
 18
 19 ⁸ NIH, *Omega-3 Supplements: In Depth*, National Center for Complementary and Integrative
 20 Health, available at [https://www.nccih.nih.gov/health/omega3-supplements-in-
 21 depth#:~:text=Use%20of%20Omega%2D3%20Supplements%20in%20the%20United%20States&te
 22 xt=The%20survey%20findings%20indicated%20that,in%20the%20previous%2030%20days](https://www.nccih.nih.gov/health/omega3-supplements-in-depth#:~:text=Use%20of%20Omega%2D3%20Supplements%20in%20the%20United%20States&text=The%20survey%20findings%20indicated%20that,in%20the%20previous%2030%20days).

22 ⁹ Global Fish Oil Market (2020 to 2027) - Opportunity Analysis and Industry Forecast -
 23 ResearchAndMarkets.com, Business Wire, available at
 24 [https://www.businesswire.com/news/home/20200909005847/en/Global-Fish-Oil-Market-2020-to-
 25 2027---Opportunity-Analysis-and-Industry-Forecast---
 26 ResearchAndMarkets.com#:~:text=The%20global%20fish%20oil%20market,and%20docosahexaen
 27 oic%20acids%20\(DHA\)](https://www.businesswire.com/news/home/20200909005847/en/Global-Fish-Oil-Market-2020-to-2027---Opportunity-Analysis-and-Industry-Forecast---ResearchAndMarkets.com#:~:text=The%20global%20fish%20oil%20market,and%20docosahexaenoic%20acids%20(DHA)).

26 ¹⁰ Hossain, M.A., *Fish as Source of Polyunsaturated Fatty Acids (PUFAs), Which One is Better-
 27 Farmed or Wild?*, *Advance Journal of Food Science and Technology* 3(6): 455, 459 (Table 2), 2011
 (“Hossain Publication”).

28 ¹¹ Breivik at 28.

1 subsequently bleached and deodorized. The resulting oil is ultimately encapsulated and sold as
 2 supplements. Below, a diagram representing the standard method for processing fish oil.¹²



18 33. Most significantly, standard fish oil is *derived using a physical, rather than a*
 19 *chemical process*, such that no chemical bonds are broken or created during the extraction,
 20 bleaching or deodorizing process. “Fish oil is produced without solvent extraction [but rather] is
 21 pressed out of the cooked fish.”¹³

22 34. The Omega-3 fatty acids in fish oil occur naturally in triglyceride form (“TAG”).
 23 Triglyceride is the term used to define the molecular structure which bond these fatty acids (i.e.,
 24

25 _____
 26 ¹² Bimbo, A. (2011). *Marine oils; edible oil processing*. AOCS Lipid Library, December 2016, available
 27 at <https://lipidlibrary.aocs.org/edible-oil-processing/marine-oils>. The graph represents the wet reduction
 28 process -- the most common method used to convert raw fish into fish oil.

¹³ Breivik at 25.

1 EPA and DHA) to a glycerol backbone. Triglycerides are the natural molecular form that make up
2 virtually all fats and oils in both animals and plants and which the human body can directly digest.¹⁴

3 35. Depending on the type of fish from which oil was derived, and the environmental
4 conditions in which that fish was raised, the ratio of EPA and DHA can differ slightly, but typically
5 will account for 30% of the fatty acid content (i.e., 180 mg of EPA and 120 mg of DHA per 1000
6 milligrams of oil).¹⁵ Standard fish oil is often referred to as “18:12,” representing the typical ratio of
7 EPA to DHA by weight (18% of the oil by weight is EPA; and 12% of the oil by weight is DHA).
8 The remaining 70% of the fish oil consists of saturated fats, other omega-3 fatty acids, omega-6 and
9 omega-9 fatty acids.¹⁶

10 C. OMEGA-3 FATTY ACID ETHYL ESTERS

11
12 36. In the early 1980’s, the Japanese pharmaceutical company Mochida developed a
13 large-scale method to synthesize EPA and DHA into an ethyl ester chemical form. The process,
14 known as trans-esterification, enabled scientists to increase the yield of omega-3s from 30% to
15 upwards of 70% as well as manipulate the ratio between types of OM3s.¹⁷ It also allowed chemists
16 to use lower grade fish oils as the starting material as rancidity due to age, storage and processing of
17 the oil are removed in the trans-esterification process and low yields of OM3s can be increased.


18
19 _____
20 ¹⁴ See, e.g., Omega3 of Norway, available at <https://norwayomega.com/omega3-fish-oil/#natural-triglycerides-vs-artificial-ethylesters> (last visited April 14, 2021).

21 ¹⁵ NIH, *Omega-3 Fatty Acids, Fact Sheet for Health Professionals*, National Institutes of Health,
22 *Office of Dietary Supplements (“NIH Fact Sheet”)* available at
<https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional>.

23 ¹⁶ Lembke, P., *Production Techniques for Omega-3 Concentrates*, Omega-6/3 Fatty Acids:
24 Functions, sustainability Strategy and Perspectives, DOI 10.1007/978-1-62703-215-5 (2013)
25 available at <https://www.puroomega.com/wp-content/uploads/2016/06/Lembke-2013-Production-Techniques-Omega-3-Human-Press-2013-pp353-364.pdf> (last visited April 14, 2021).

26
27 ¹⁷ Klinik, M., *A Review of Omega-3 Ethyl Esters for Cardiovascular Prevention and Treatment of*
28 *Increased Blood Triglyceride Levels*, Vasc Health Risk Manag (2006), doi:
10.2147/vhrm.2006.2.3.251.

1 the distillation process, but typically ranges from 50-70%.² The constituent compounds are DHA
 2 Ethyl Esters and EPA Ethyl Esters — which are molecularly distinct from the precursor DHA and
 3 EPA triglyceride molecules. The diagram below shows the most common trans-esterification process
 4 beginning with crude fish oil and resulting in the formation of ethyl esters.²²



15 40. The trans-esterification process allows manufacturers to do one of several things that
 16 yield significant financial benefits: (1) Increase the levels of EPA-EE and DHA-EE far in excess of
 17 the 18/12 limit of TAG EPA and TAG DHA in fish oil. Where the standard fish oil typically yields
 18 only 30% DHA/EPA by volume, trans-esterification allows manufacturers to obtain DHA-EE and
 19 EPA-EE that yields upwards of 70% by volume; (2) Alter the natural ratios of DHA/EPA (i.e., 120
 20 mg / 180 mg per 1000 mg) to create DHA-EE / EPA-EE in any ratio the manufacturer desires; (3)
 21 Use low grade crude fish oil generated from fish offal -- heads, viscera and other body parts
 22 discarded in preparing fish for consumption (i.e. fish waste) -- in lieu of a whole small oily fish (e.g.,
 23 sardine, anchovy, menhaden) that are traditionally caught and processed for the production of fish
 24 oil. In addition to being low quality, offal produces small volumes of oil compared to whole fish

27 ²² Bimbo, A.P. *Processing of marine oils*. In: *Long Chain Omega-3 Specialty Oils*, pp. 77-109 (H.
 28 Breivik (ed.) The Oily Press Bridgwater England) (2007).

1 because these edible species are primarily non-fatty fish.²³ For example, a study exploring the
2 efficiency of extracting oil from the heads of two tuna species, found the crude oil yields are only
3 between 1-2%, far less than the average 30% yield from whole fish species that are caught
4 specifically for rendering of fish oil.²⁴ Inconsistent and low yields, in addition to the fact that the raw
5 materials consist of fish waste renders the resulting crude fish oil unsuitable for human consumption
6 and requires trans-esterification to create a useable yield.²⁵

7 41. At the end of the trans-esterification process, the crude fish oil has been substantially
8 transformed into Fatty Acid Ethyl Esters consisting of DHA-EE, EPA-EE and other OM3 fatty acid
9 ethyl esters. At this point, the solution may be encapsulated and sold as a dietary supplement, or
10 further concentrated, refined and sold as a drug.²⁶

11 42. Ultimately, once trans-esterified, fish oil is substantially and irrevocably transformed
12 into Omega-3 fatty acid ethyl esters -- a substance that cannot be found in any part of any fish.
13 Calling it “fish oil,” therefore, is fraudulent, deceptive and misleading.

14 **D. OMEGA-3 FATTY ACID ETHYL ESTERS ARE NOT FISH OIL**

15 **(1) *DHA & EPA Ethyl Esters are Different Molecules than DHA & EPA*** 16 ***Found in Natural Fish Oil***

17 43. The trans-esterification process substantially and irrevocably transforms the Omega-
18 3s in fish oil from their natural triglyceride form into Omega-3 fatty acid ethyl esters. Critically,

20 ²³ Bimbo, A. (2011). Marine oils; edible oil processing. AOCS Lipid Library, December 2016,
21 available at <http://lipidlibrary.aocs.org/OilsFats/content.cfm?ItemNumber=40332>

22 ²⁴ Kasmiran, B. 2018. Comparison and evaluation of the quality of fish oil and fishmeal extracted from
23 the heads of Yellowfin tuna (*Thunnus albacares*) and Albacore tuna (*Thunnus alalunga*). Nations
24 University Fisheries Training Programme, Iceland, available at
<http://www.unuftp.is/static/fellows/document/britney16prf.pdf>.



25 ²⁵ Alfio, V, et al, *From Fish Waste to Value: An Overview of the Sustainable Recovery of Omega-3*
26 *for Food Supplements*, Molecules. 2021 Feb; 26(4): 1002. Published online 2021 Feb 13. doi:
10.3390/molecules26041002 available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918619/>

27 ²⁶ See e.g., Lovaza Prescribing information available at
28 https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021654s023lbl.pdf.

1 these substances, (fish oil and omega-3 fatty acid ethyl esters), are distinguishable on a molecular
 2 level such that it is impossible as a matter of law or logic for them to share a common or usual name.
 3 Indeed, they do not. Along with their molecular differences, they have different common or usual
 4 names which must be properly represented on labeling of any dietary supplement in which they are
 5 contained. To do otherwise is deceptive, misleading, fraudulent and illegal.

	DHA ²⁷	DHA-EE ²⁸
Empirical Formulae	C ₂₂ H ₃₂ O ₂	C ₂₄ H ₃₆ O ₂
Molecular Weight	328.50 g/mol	356.55 g/mol
Synonyms	Docosahexaenoic acid Cervonic acid, Doconexento Doconexentum Doxonexent Docosahexaenoate	Docosahexaenoic acid ethyl ester Ethyl docosahexaenoate Cervonic acid ethyl ester

13 Molecular 14 Structures





25
26 ²⁷ See NIH, National Library of Medicine available at
<https://pubchem.ncbi.nlm.nih.gov/compound/445580>

27 ²⁸ See NIH, National Library of Medicine available at
<https://pubchem.ncbi.nlm.nih.gov/compound/9831416>
 28

	EPA ²⁹	EPA-EE ³⁰
Empirical Formulae	C₂₀H₃₀O₂	C₂₂H₃₄O₂
Molecular Weight	302.5 g/mol	330.51
Synonyms	Eicosapentaenoic acid Icosapent, 10417-94-4 Icosapento Icosapentum Timnodonic acid	Eicosapentaenoic acid ethyl ester Epadel Ethyl eicosapentaenoate Ethyl eicosapentaenoic acid Ethyl icosapentaenoate Ethyl icosapentate Ethyl-eicosapentaenoic acid Ethyl-EPA Icosapentaenoate icosapentate Icosapent ethyl Timnodonic acid ethyl ester


Molecular Structures



²⁹ Pub Chem, available at <https://pubchem.ncbi.nlm.nih.gov/compound/446284>

³⁰ Pub Chem, available at <https://pubchem.ncbi.nlm.nih.gov/compound/9831415>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28



48. In addition to the USP, numerous other industry and scientific authorities independently confirm the differences between fish oil and omega-3 fatty acid ethyl esters.

49. Codex Alimentarius Commission (“Codex”) was created in 1963 by two U.N. organizations, the Food and Agriculture Organization and the World Health Organization. Its main purpose is to protect the health of consumers and to ensure fair practices in international trade in food through the development of food standards, codes of practice, guidelines and other recommendations. Codex standards and guidelines are developed by committees, which are open to all member countries. Member countries review and provide comments on Codex standards and related texts at several stages in the development process. In the United States, public meetings are held to receive comments on Codex drafts and comments are invited from all interested parties.

1 Although Codex standards and related texts are voluntary, they do provide a template for laws and
2 are used by the World Trade Organization as an agreed benchmark in global trade disputes.³³

3 50. FDA participates and exercises leadership in the Codex Alimentarius Commission.
4 The objective of FDA’s participation in Codex is to develop science-based international food safety,
5 labeling, and other pertinent standards that provide consumer protection, labeling information, and
6 prevention of economic fraud and deception that are consistent with U.S. regulations and laws.

7 51. FDA uses procedures that promote consumer protection and transparency, as it works
8 with the U.S. Codex Office to develop U.S. Delegation positions on matters before relevant Codex
9 committees.³⁴

10 52. In 2017, the Codex Alimentarius Committee adopted standards for fish oil. It was a
11 long process that started in 2011 “involving many discussions on the finer details which was
12 important to clarify as the purpose of this Standard is to protect consumer health and promote fair
13 practices in the trade of fish oil.”³⁵ Significantly, the Codex, like the USP, recognizes and draws a
14 distinction between natural fish oil and trans-esterified products.³⁶

17
18 ³³ FDA, *Responses to Questions about Codex and Dietary Supplements*, available
19 [https://www.fda.gov/food/dietary-supplements-guidance-documents-regulatory-](https://www.fda.gov/food/dietary-supplements-guidance-documents-regulatory-information/responses-questions-about-codex-and-dietary-supplements#what)
20 [information/responses-questions-about-codex-and-dietary-supplements#what](https://www.fda.gov/food/dietary-supplements-guidance-documents-regulatory-information/responses-questions-about-codex-and-dietary-supplements#what) (last visited April 13,
21 2021).

22 ³⁴ FDA, *FDA's Participation in Codex*, available at [https://www.fda.gov/food/international-](https://www.fda.gov/food/international-cooperation-food-safety/fdas-participation-codex)
23 [cooperation-food-safety/fdas-participation-codex](https://www.fda.gov/food/international-cooperation-food-safety/fdas-participation-codex) (last visited April 13, 2021).

24 ³⁵ IFFO, *CODEX Standard for Fish Oil*, available at <https://www.iffonet.net/codex-standard-fish-oil>
25 (last visited April 13, 2021).

26 ³⁶ Section 2.2 defines “Fish oils” as those derived from one or more species of fish or shellfish.³⁶ In
27 contrast, Section 2.6 defines “Concentrated fish oils ethyl esters” as those derived from fish oils
28 described in Section 2.1 to 2.4 and are primarily composed of fatty acids ethyl esters. See, *Report of
the U.S. Delegate, 25th Session, Codex Committee on Fats and Oils, United States Department of
Agriculture*, available at [https://www.usda.gov/sites/default/files/documents/delegates-report-](https://www.usda.gov/sites/default/files/documents/delegates-report-02272017.pdf)
[02272017.pdf](https://www.usda.gov/sites/default/files/documents/delegates-report-02272017.pdf) (last visited April 13, 2021).

1 56. On several occasions the CPB considered the appropriate tariff classification for
2 Omega-3 Acid Ethyl Esters. Consistently, the CPB recognized that trans-esterification substantially
3 transforms fish oil into a different product which results in a different tariff classification.

4 57. In 2011, the CPB tested and reviewed a product that was described as “a gelatin
5 capsule containing 1000 milligrams of fish oil, said to be derived from anchovy, sardine, herring or
6 other fish species.” The CPB determined that the “fish oil” had been substantially transformed from
7 its original fish oil source -- “the crude fish oil has been refined and chemically modified by
8 deodorizing, ethylating (conversion of triglycerides to ethyl esters), distillation, winterizing/cold
9 filtrating, bleaching and drumming.” Accordingly, while the petitioner sought to classify the trans
10 esterified product under Section 1504.20.4000 of the HTS which pertains to “fish-liver oils and their
11 fractions, whether or not refined, *but not chemically modified*,” the CPB concluded that “[b]ased on
12 the manufacturing process of the fish oil, they will be classified elsewhere.... The applicable
13 subheading for these products will be 2106.90.9998, HTSUS, which provides for food preparations
14 not elsewhere specified or included...other...other...other. The duty rate will be 6.4 percent ad
15 valorem.” (emphasis added).⁴⁰

16 58. Just as an apple cannot be called a pear, an omega-3 acid ethyl ester cannot be called
17 fish oil. As a significant seller of dietary supplements and the best selling “Fish Oil” supplement on
18 Amazon, MRC’s obligation to label its Products truthfully and accurately are even more compelling.
19
20

21 ⁴⁰ Customs Ruling, N171795, July 5, 2011, available at
22 <https://rulings.cbp.gov/search?term=N171795&collection=ALL&sortBy=RELEVANCE&pageSize=30&page=1>; *See also*, HQ H295287 (June 18, 2020) available at
23 <https://rulings.cbp.gov/search?term=HQ%20H295287&collection=ALL&sortBy=RELEVANCE&pageSize=30&page=1> (“CBP has a long-standing position that in order to be classified in Chapter 15,
24 HTSUS, as fats or oils, products must predominantly be composed of triglycerides. See
25 Headquarters Ruling Letter (“HQ”) H102457, dated September 8, 2010; HQ 963166, dated
26 December 11, 2001; HQ 965396, dated July 23, 2002; HQ 964531, dated March 14, 2002; HQ
27 965699, dated September 25, 2002; New York Ruling Letter (“NY”) N234974, dated November 19,
28 2012.... Accordingly, only products composed primarily of triglycerides are classifiable under
heading 1515, HTSUS.”); *See, also*, United States Pharmacopeia – National Formulary monograph
catalog confirming different HTSUS as between fish oil and Omega-3 Fatty Acids.

1 At bottom, this Product is a fatty acid ethyl ester. Labeling and selling it as fish oil is false,
2 misleading, deceptive and unlawful.

3
4 **SPECIFIC LABELING VIOLATIONS**

5 59. The Federal Food, Drug & Cosmetic Act (“FDCA”) broadly regulates the sale of
6 food and beverages to the consuming public. 21 U.S.C §301. It was promulgated in significant part
7 to prevent consumer deception and was principally implemented through the creation of a uniform
8 system of labeling on which consumers could rely to make informed purchasing decisions.

9 60. The FDCA prohibits the misbranding of any food. 21 U.S.C. §331(b). Generally, a
10 food is misbranded if, among other things, its labeling is false or misleading. 21 U.S.C. § 343.

11 61. The Nutrition Labeling and Education Act of 1990 amended the FDCA by requiring
12 that most foods, including dietary supplements, bear nutrition labeling. Subsequently, the Dietary
13 Supplement Health and Education Act of 1994 (“DSHEA”) amended the Act, in part, by defining
14 "dietary supplements," adding specific labeling requirements for dietary supplements, and providing
15 for optional labeling statements.

16 62. Dietary supplements must bear labeling in accordance with applicable provisions of
17 FDCA. The MRC Product labels not only violate the clear mandates of the FDCA, but are
18 independently false, misleading, and operate as a deception on the consuming public.

19 **(1) *Fish Oil is Not the Common or Usual Name of This Product***

20 63. The principal display panel (“PDP”) of the MRC Product describes the supplement as
21 a Triple Strength “Fish Oil” containing “2000 mg of Fish Oil consisting of 800 mg of EPA and 600
22 mg of DHA.

23
24 **Section 21 C.F.R. 101.3** states in relevant part:

25
26 (a) The principal display panel of a food in package form shall bear as one of its
27 principal features a statement of the identity of the commodity. (b) Such statement of
28 identity shall be in terms of: (1) The name now or hereafter specified in or required
by any applicable Federal law or regulation; or, in the absence thereof, (2) The
common or usual name of the food; or, in the absence thereof (3) An appropriately

1 descriptive term, or when the nature of the food is obvious, a fanciful name
2 commonly used by the public for such food.

3 64. The statement of identity for a dietary supplement is the name that appears on the
4 label of the dietary supplement. As a general matter, the statement of identity of a dietary
5 supplement is the name specified by federal law or regulation, or, if no such name is specified, its
6 common or usual name.⁴¹

7 65. As demonstrated in great detail herein, Fish Oil and Omega-3 Acid Ethyl Esters are
8 not the same. They are different on a molecular level and have different common and usual names.

9 66. It is indisputable that the MRC Products were trans-esterified – a process that
10 substantially transformed what was once natural fish oil containing OM3s in triglyceride form into a
11 synthetic product consisting of fatty acid ethyl esters.

12 67. MRC’s failure to identify its Product by its common and usual name, obfuscated the
13 most important information that is conveyed about a product – its name and contents. By failing to
14 properly name its Products, MRC has deceived Plaintiff and members of the class, depriving them of
15 a consumer’s most basic right to make an informed purchasing decision.

16 **(2) *The Supplement Fact Section is False and Misleading***

17 68. Unfortunately for Plaintiff and members of the class, the misrepresentation on the
18 Principal Display Panel is further exacerbated by misrepresentations on the Supplement Facts panel
19 on the back of the label.

20
21
22
23
24
25
26 ⁴¹ See, 21 U.S.C. 321(ff)(2)(C), 21 U.S.C. 343(s)(2)(B), 21 CFR §101.1 and 21 CFR §101.3; FDA
27 Dietary Supplement Labeling Guide “FDA Labeling Guide”) available at
28 <https://www.fda.gov/food/dietary-supplements-guidance-documents-regulatory-information/dietary-supplement-labeling-guide-chapter-ii-identity-statement>.

1
2
3
4
5
6
7
8
9
10
11
12

Supplement Facts		
Serving Size: 2 Softgels		
Servings Per Container: 90		
Amount Per Serving	% Daily Value**	
Calories	20	
Calories from Fat	20	
Total Fat	2 g	3%
Fish Oil	2,000 mg	*
Typically Providing:		
EPA (Eicosapentaenoic Acid)	800 mg	*
DHA (Docosahexaenoic Acid)	600 mg	*
**Percent Daily Values are based off a 2000 calorie diet. *Daily Value not established.		

13 69. Supplement manufacturers are generally required to disclose all ingredients contained
14 in their products. 21 C.F.R. §101.36. The obligation to describe those ingredients by their common
15 or usual name applies with same force in the Supplement Fact section as it does on the principal
16 display panel. As detailed above, the common or usual name of the contents of this Product is an
17 Omega-3 fatty acid ethyl esters and not “Fish Oil.” Moreover, the Supplement Facts erroneously
18 claim the Product contains EPA and DHA, which it does not. This Product contains 0 mg of
19 Eicosapentaenoic acid (EPA) and 0 mg Docosahexaenoic acid (DHA) as demonstrated in the
20 comparative mass spectra above. Once trans-esterified, the EPA in fish was substantively modified
21 into ethyl icosapentate (aka Eicosapentaenoic acid ethyl ester) (EPA-EE) a molecule separate and
22 distinct from EPA. Similarly, the Docosahexaenoic acid (DHA) in fish oil, once trans-esterified,
23 was substantively modified into ethyl docosahexaenate (aka Docosahexaenoic acid ethyl ester)
24 (DHA-EE), a molecule sperate and distinct from DHA. Although both DHA-and DHA-EE may be
25 listed by any number of synonyms, critically, none of their synonyms are shared. Failure to properly
26 identify EPA-EE and DHA-EE as constituent ingredients violates the mandates of the FDCA and
27 independently renders the Products’ Supplement Fact section false and misleading under state
28 consumer protection laws.

CLASS ACTION ALLEGATIONS

1
2 90. Plaintiff brings this action on behalf of himself and on behalf of classes of all others
3 similarly situated consumers defined as follows:

- 4 a. **National:** All persons in the United States who purchased MRC’s Product in
5 the United States during the Class Period.
6 b. **California:** All persons in California who purchased MRC’s Product in
7 California during the Class Period.
8 c. **Class Period** is the maximum time allowable as determined by the statute of
9 limitation periods accompanying each cause of action.

10 91. Plaintiff brings this Class pursuant to Federal Rule of Civil Procedure 23(a), and
11 23(b)(1), 23(b)(2), 23(b)(3) and 23(c)(4).

12 92. Excluded from the Classes are: (i) Defendant and their employees, principals,
13 affiliated entities, legal representatives, successors and assigns; and (ii) the judges to whom this
14 action is assigned.

15 93. Upon information and belief, there are tens of thousands of members of the Class.
16 Therefore, individual joinder of all members of the Class would be impracticable.

17 94. There is a well-defined community of interest in the questions of law and fact
18 affecting the parties represented in this action.

19 95. Common questions of law or fact exist as to all members of the Class. These
20 questions predominate over the questions affecting only individual Class members. These common
21 legal or factual questions include but are not limited to:

- 22 a. Whether Defendant marketed, packaged, or sold the Class Products to
23 Plaintiff and those similarly situated using false, misleading, or
24 deceptive statements or representations;
25 b. Whether Defendant omitted or misrepresented material facts in
26 connection with the sales of their Products;
27 c. Whether Defendant participated in and pursued the common course of
28 conduct complained of herein;

- 1 d. Whether Defendant has been unjustly enriched as a result of their
- 2 unlawful business practices;
- 3 e. Whether Defendant’s actions violate the Unfair Competition Law, Cal.
- 4 Bus. & Prof. Code §§17200, *et seq.* (the “UCL”);
- 5 f. Whether Defendant’s actions violate the False Advertising Law, Cal.
- 6 Bus. & Prof. Code §§17500, *et seq.* (the “FAL”);
- 7 g. Whether Defendant’s actions violate the Consumers Legal Remedies
- 8 Act, Cal. Civ. Code §§1750, *et seq.* (the “CLRA”);
- 9 h. Whether Defendant’s actions constitute breach of express warranty;
- 10 i. Whether Defendant’s should be enjoined from continuing the above-
- 11 described practices;
- 12 j. Whether Plaintiff and members of the Class are entitled to declaratory
- 13 relief; and
- 14 k. Whether Defendant’s should be required to make restitution, disgorge
- 15 profits, reimburse losses, and pay damages as a result of the above-
- 16 described practices.

17 96. Plaintiff’s claims are typical of the claims of the Class, in that Plaintiff was a
18 consumer who purchased Defendant’s Product. Plaintiff is no different in any relevant respect from
19 any other Class member who purchased the Product, and the relief sought is common to the Class.

20 97. Plaintiff is an adequate representative of the Class because his interests do not
21 conflict with the interests of the members of the Class he seeks to represent, and he has retained
22 counsel competent and experienced in conducting complex class action litigation. Plaintiff and his
23 counsel will adequately protect the interests of the Class.

24 98. A class action is superior to other available means for the fair and efficient
25 adjudication of this dispute. The damages suffered by each individual Class member likely will be
26 relatively small, especially given the cost of the Products at issue and the burden and expense of
27 individual prosecution of the complex litigation necessitated by Defendant’s conduct. Thus, it would
28 be virtually impossible for members of the Class individually to effectively redress the wrongs done

1 to them. Moreover, even if members of the Class could afford individual actions, it would still not be
2 preferable to class-wide litigation. Individualized actions present the potential for inconsistent or
3 contradictory judgments. By contrast, a class action presents far fewer management difficulties and
4 provides the benefits of single adjudication, economies of scale, and comprehensive supervision by a
5 single court.

6 99. In the alternative, the Class may be certified because Defendant has acted or refused
7 to act on grounds generally applicable to the Class, thereby making appropriate preliminary and final
8 equitable relief with respect to each Class.

9 100. The requirements for maintaining a class action pursuant to Rule 23(b)(2) are also
10 met, as Defendant has acted or refused to act on grounds generally applicable to the Class, thereby
11 making appropriate final injunctive relief or corresponding declaratory relief with respect to the
12 Class as a whole.

13
14 **FIRST CAUSE OF ACTION**

15 **Unlawful Business Practices**
16 **Violation of The Unfair Competition Law (“UCL”)**
17 **Bus. & Prof. Code §§17200, *et seq.***

18 101. Plaintiff incorporates each and every allegation contained in the paragraphs above as
19 if restated herein.

20 102. The UCL defines unfair business competition to include any “unlawful, unfair or
21 fraudulent” act or practice, as well as any “unfair, deceptive, untrue or misleading” advertising. Cal.
22 Bus. Prof. Code §17200.

23 103. A business act or practice is “unlawful” if it violates any established state or federal
24 law.

25 104. Defendant’s acts, omissions, misrepresentations, practices, and/or non-disclosures
26 concerning the Products alleged herein, constitute “unlawful” business acts and practices in that they
27 violate the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§301, *et seq.* and its implementing
28 regulations, including, at least, the following sections:

- 1 a. 21 U.S.C. §343(a), which deems food misbranded when its labeling contains a
- 2 statement that is false or misleading in any particular;
- 3 b. 21 C.F.R. §102.5(a)-(d), which prohibits the naming of foods so as to create
- 4 an erroneous impression about the presence or absence of ingredient(s) or
- 5 component(s) therein;
- 6 c. 21 U.S.C. §§331 and 333, which prohibits the introduction of misbranded
- 7 foods into interstate commerce.
- 8 d. 21 C.F.R. §101.3 and 21 C.F.R. §101.36 as described above, pertaining to,
- 9 *inter alia*, use of common or usual names.

10 105. California has expressly adopted federal labeling requirements as its own pursuant to
11 the Sherman Food, Drug, and Cosmetic Law, CAL. HEALTH & SAFETY CODE § 109875 et seq.
12 (the “Sherman Law”), the Sherman Law, which provides that “[a]ll food labeling regulations and
13 any amendments to those regulations adopted pursuant to the federal act, in effect on January 1,
14 1993, or adopted on or after that date shall be the food regulations of this state.” CAL. HEALTH &
15 SAFETY CODE § 110100.

16 106. This identical conduct serves as the sole factual basis of each cause of action brought
17 by this Complaint, and Plaintiff does not seek to enforce any of the state law claims to impose any
18 standard of conduct that exceeds that which would violate the FDCA.

19 107. Each of MRC’s violations of federal law and regulations violates California’s
20 Sherman Food, Drug, and Cosmetic Law, CAL. HEALTH & SAFETY CODE § 109875 et seq. (the
21 “Sherman Law”), including, but not limited to, the following sections:

22 108. Section 110100 (adopting all FDA regulations as state regulations);

23 109. Section 110290 (“In determining whether the labeling or advertisement of a food . . .
24 is misleading, all representations made or suggested by statement, word, design, device, sound, or
25 any combination of these, shall be taken into account.”);

26 110. Section 110390 (“It is unlawful for any person to disseminate any false advertisement
27 of any food. . . . An advertisement is false if it is false or misleading in any particular.”);

1 111. Section 110395 (“It is unlawful for any person to manufacture, sell, deliver, hold, or
2 offer for sale any food . . . that is falsely advertised.”);

3 112. Section 110398 (“It is unlawful for any person to advertise any food, drug, device, or
4 cosmetic that is adulterated or misbranded.”);

5 113. Section 110400 (“It is unlawful for any person to receive in commerce any food . . .
6 that is falsely advertised or to deliver or proffer for delivery any such food”); and

7 114. Section 110660 (“Any food is misbranded if its labeling is false or misleading in any
8 particular.”).

9 115. Each of the challenged omissions, statements, and actions by MRC violates the
10 FDCA, and the Sherman Law, and, consequently, violates the “unlawful” prong of the UCL.

11 116. MRC’s conduct is further “unlawful” because it violates California’s False
12 Advertising Law, CAL. BUS. & PROF. CODE § 17500 et seq. (the “FAL”), and California’s
13 Consumers Legal Remedies Act, CAL. CIV. CODE § 1750 et seq. (the “CLRA”), as discussed in
14 the claims below.

15 117. By committing the unlawful acts and practices alleged above, Defendants have
16 engaged, and continue to be engaged, in unlawful business practices within the meaning of
17 California Business and Professions Code §§17200, *et seq.*

18 118. Through their unlawful acts and practices, Defendant has obtained, and continues to
19 unfairly obtain, money from members of the Class. As such, Plaintiff requests that this Court cause
20 Defendant to restore this money to Plaintiff and all members of the Class, to disgorge the profits
21 Defendant made on these transactions, and to enjoin Defendant from continuing to violate the Unfair
22 Competition Law or violating it in the same fashion in the future. Otherwise, the Class may be
23 irreparably harmed and denied an effective and complete remedy if such an order is not granted.

24
25
26
27
28

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

SECOND CAUSE OF ACTION
Unfair Business Practices
Violation of The Unfair Competition Law
Bus. & Prof. Code §§ 17200, *et seq.*

119. Plaintiff incorporates each and every allegation contained in the paragraphs above as if restated herein.

120. The UCL defines unfair business competition to include any “unlawful, unfair or fraudulent” act or practice, as well as any “unfair, deceptive, untrue or misleading” advertising. Cal. Bus. Prof. Code §17200.

121. A business act or practice is “unfair” under the Unfair Competition Law if the reasons, justifications and motives of the alleged wrongdoer are outweighed by the gravity of the harm to the alleged victims.

122. Defendant has violated, and continue to violate, the “unfair” prong of the UCL through their misleading description of the Product. The gravity of the harm to members of the Class resulting from such unfair acts and practices outweighs any conceivable reasons, justifications, or motives of Defendant for engaging in such deceptive acts and practices. By committing the acts and practices alleged above, Defendant engaged, and continued to engage, in unfair business practices within the meaning of California Business and Professions Code §§17200, *et seq.*

123. Through their unfair acts and practices, Defendant obtained, and continued to unfairly obtain, money from members of the Class. As such, Plaintiff has been injured and requests that this Court cause Defendant to restore this money to Plaintiff and the members of the Class, to disgorge the profits Defendant made on their Products, and to enjoin Defendant from continuing to violate the Unfair Competition Law or violating it in the same fashion in the future. Otherwise, the Class may be irreparably harmed and denied an effective and complete remedy if such an Order is not granted.

THIRD CAUSE OF ACTION

**Fraudulent Business Practices
Violation of The Unfair Competition Law
Bus. & Prof. Code §§ 17200, *et seq.***

1
2
3 124. Plaintiff incorporates each and every allegation contained in the paragraphs above as
4 if restated herein.

5 125. The UCL defines unfair business competition to include any “unlawful, unfair or
6 fraudulent” act or practice, as well as any “unfair, deceptive, untrue or misleading” advertising. Cal.
7 Bus. & Prof. Code §17200.

8 126. A business act or practice is “fraudulent” under the Unfair Competition Law if it
9 actually deceives or is likely to deceive members of the consuming public.

10 127. Defendant’s acts and practices of mislabeling their Products in a manner to suggest
11 they principally contained their characterizing ingredients.

12 128. As a result of the conduct described above, Defendant has been, and will continue to
13 be, unjustly enriched at the expense of Plaintiff and members of the proposed Class. Specifically,
14 Defendant has been unjustly enriched by the profits they have obtained from Plaintiff and the Class
15 from the purchases of its Products.

16 129. Through their fraudulent acts and practices, Defendant has improperly obtained, and
17 continue to improperly obtain, money from members of the Class. As such, Plaintiff requests that
18 this Court cause Defendant to restore this money to Plaintiff and the Class, to disgorge the profits
19 Defendant has made, and to enjoin Defendants from continuing to violate the Unfair Competition
20 Law or violating it in the same fashion in the future. Otherwise, the Class may be irreparably harmed
21 and denied an effective and complete remedy if such an Order is not granted.
22
23
24
25
26
27
28

FOURTH CAUSE OF ACTION

False Advertising

Violation of California Bus. & Prof. Code §§ 17500, *et seq.*

1
2
3 130. Plaintiff incorporates each and every allegation contained in the paragraphs above as
4 if restated herein.

5 131. Defendant uses advertising and packaging to sell its Products. Defendant
6 disseminates advertising regarding its Products which by their very nature are deceptive, untrue, or
7 misleading within the meaning of California Business & Professions Code §§17500, *et seq.* because
8 those advertising statements contained on the labels are misleading and likely to deceive, and
9 continue to deceive, members of the putative Class and the general public.

10 132. In making and disseminating the statements alleged herein, Defendant knew or should
11 have known that the statements were untrue or misleading, and acted in violation of California
12 Business & Professions Code §§17500, *et seq.*

13 133. The misrepresentations and non-disclosures by Defendant of the material facts
14 detailed above constitute false and misleading advertising and therefore constitute a violation of
15 California Business & Professions Code §§17500, *et seq.*

16 134. Through their deceptive acts and practices, Defendant has improperly and illegally
17 obtained money from Plaintiff and the members of the Class. As such, Plaintiff requests that this
18 Court cause Defendants to restore this money to Plaintiff and the members of the Class, and to
19 enjoin Defendant from continuing to violate California Business & Professions Code §§17500, *et*
20 *seq.*, as discussed above. Otherwise, Plaintiff and those similarly situated will continue to be harmed
21 by Defendant's false and/or misleading advertising.

22 135. Pursuant to California Business & Professions Code §17535, Plaintiff seeks an Order
23 of this Court ordering Defendants to fully disclose the true nature of their misrepresentations.
24 Plaintiff additionally requests an Order: (1) requiring Defendant to disgorge its ill-gotten gains, (2)
25 award full restitution of all monies wrongfully acquired by Defendant and (3), interest and attorneys'
26 fees. Plaintiff and the Class may be irreparably harmed and denied an effective and complete remedy
27 if such an Order is not granted.
28

FIFTH CAUSE OF ACTION

**Violation of the Consumers Legal Remedies Act
California Civil Code §§ 1750, *et seq.***

1
2
3
4 136. Plaintiff incorporates each and every allegation contained in the paragraphs above as
5 if restated herein.

6 137. This cause of action is brought pursuant to the Consumers Legal Remedies Act,
7 California Civil Code §§1750, *et seq.* (the “CLRA”).

8 138. Plaintiff and each member of the proposed Class are “consumers” within the meaning
9 of Civil Code §1761(d).

10 139. The purchases of the Products by consumers constitute “transactions” within the
11 meaning of Civil Code §1761(e) and the Products constitute “goods” within the meaning of Civil
12 Code §1761(a).

13 140. Defendant has violated, and continue to violate, the CLRA in at least the following
14 respects:

- 15 a. §1770(5) pertaining to misrepresentations regarding the characteristics of
16 goods sold—specifying that misleading representations regarding ingredients
17 violate the CLRA;
18 b. §1770(7) pertaining to misrepresentations regarding the standard, quality, or
19 grade of goods sold; and
20 c. § 1770(9) pertaining to goods advertised with the intent not to provide what is
21 advertised.

22 141. Defendant knew, or should have known, that the labeling of their Products violated
23 consumer protection laws, and that these statements would be relied upon by Plaintiff and the
24 members of the Class.

25 142. The representations were made to Plaintiff and all members of the Class. Plaintiff
26 relied on the accuracy of the representations on Defendant’s labels which formed a material basis for
27 his decision to purchase the Products. Moreover, based on the very materiality of Defendant’s
28

1 misrepresentations uniformly made on or omitted from their Product labels, reliance may be
2 presumed or inferred for all members of the Class.

3 143. Defendant carried out the scheme set forth in this Complaint willfully, wantonly, and
4 with reckless disregard for the interests of Plaintiff and the Class, and as a result, Plaintiff and the
5 Class have suffered an ascertainable loss of money or property.

6 144. Plaintiff and the members of the Class request that this Court enjoin Defendants from
7 continuing to engage in the unlawful and deceptive methods, acts and practices alleged above,
8 pursuant to California Civil Code §1780(a)(2). Unless Defendant is permanently enjoined from
9 continuing to engage in such violations of the CLRA, future consumers of Defendant's Products will
10 be damaged by their acts and practices in the same way as have Plaintiff and the members of the
11 proposed Class.

12 145. On or about March 2, 2021, Plaintiff transmitted his CLRA demand pursuant to Civil
13 Code §1782, notifying Defendant of the conduct described herein and that such conduct was in
14 violation of particular provisions of Civil Code §1770. The demand was received on March 31,
15 2021. As of this date, MRC has not taken any action to address the demand. Accordingly, Plaintiff
16 seek damages pursuant to Civil Code § 1780(a).

17
18 **SIXTH CAUSE OF ACTION**

19 **Breach of Express Warranty**

20 146. Plaintiff incorporates each and every allegation contained in the paragraphs above as
21 if rewritten herein.

22 147. Plaintiff's express warranty claims are based on violations Cal. Com. Code §2313.

23 148. Defendant made express warranties to Plaintiff and members of the Class that the
24 Products they purchased consisted of real fish oil in its triglyceride form; that its constituent
25 components were DHA and EPA (as opposed to DHA-EE and EPA-EE).

26 149. The express warranties made to Plaintiff and members of the Class appear on every
27 Product label. This warranty regarding the nature of the Product marketed by Defendant specifically
28 relates to the goods being purchased and became the basis of the bargain.

1 150. Plaintiff and the Class purchased the Products in the belief that they conformed to the
2 express warranties that were made on the Products' labels.

3 151. Defendant breached the express warranties made to Plaintiff and members of the
4 Class by failing to supply goods that conformed to the warranties it made. As a result, Plaintiff and
5 members of the Class suffered injury and deserve to be compensated for the damages they suffered.

6 152. Plaintiff and the members of the Class paid money for the Products. However,
7 Plaintiff and the members of the Class did not obtain the full value of the advertised Products. If
8 Plaintiff and other members of the Class had known of the true nature of the Products, they would
9 not have purchased them or paid less for them. Accordingly, Plaintiff and members of the Class have
10 suffered injury in fact and lost money or property as a result of Defendant's wrongful conduct.

11 153. Plaintiff and the Class are therefore entitled to recover damages, punitive damages,
12 equitable relief such as restitution and disgorgement of profits, and declaratory and injunctive relief.

13
14
SEVENTH CAUSE OF ACTION

15 **Restitution Based On Quasi-Contract/Unjust Enrichment**

16 154. Plaintiff incorporates each and every allegation contained in the paragraphs above as
17 if rewritten herein.

18 155. Defendant's conduct in enticing Plaintiff and the Class to purchase their Products
19 with false and misleading packaging is unlawful because the statements contained on the
20 Defendant's Product labels are untrue.

21 156. Defendant's took monies from Plaintiff and the Class for these Products and have
22 been unjustly enriched at the expense of Plaintiff and the Class as result of their unlawful conduct
23 alleged herein, thereby creating a quasi-contractual obligation on Defendant to restore these ill-
24 gotten gains to Plaintiff and the Class. It is against equity and good conscience to permit Defendant
25 to retain the ill-gotten benefits received from Plaintiff and Class members.

26 157. As a direct and proximate result of Defendant's unjust enrichment, Plaintiff and the
27 Class are entitled to restitution or restitutionary disgorgement in an amount to be proved at trial.

PRAYER FOR RELIEF

1
2 THEREFORE, Plaintiff, on behalf of himself and on behalf of the other members of the
3 Class and for the Counts so applicable on behalf of the general public request an award and relief as
4 follows:

5 A. An order certifying that this action is properly brought and may be maintained as a
6 class action, that Plaintiff be appointed Class Representative, and Plaintiff’s counsel be appointed
7 Lead Counsel for the Class.

8 B. Restitution in such amount that Plaintiff and all members of the Class paid to
9 purchase Defendant’s Product or restitutionary disgorgement of the profits Defendant obtained from
10 those transactions, for Causes of Action for which they are available.

11 C. Compensatory damages for Causes of Action for which they are available.

12 D. Statutory penalties for Causes of Action for which they are available.

13 E. Punitive Damages for Causes of Action for which they are available.

14 F. A declaration and Order enjoining Defendant from marketing and labeling their
15 Products deceptively, in violation of laws and regulations as specified in this Complaint.

16 G. An Order awarding Plaintiff his costs of suit, including reasonable attorneys’ fees and
17 pre and post judgment interest.

18 H. An Order requiring an accounting for, and imposition of, a constructive trust upon all
19 monies received by Defendant as a result of the unfair, misleading, fraudulent and unlawful conduct
20 alleged herein.

21 I. Such other and further relief as may be deemed necessary or appropriate.
22
23
24
25
26
27
28

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

DEMAND FOR JURY TRIAL

Plaintiff hereby demands a trial by jury on all causes of action or issues so triable.

DATED: May 28, 2021

Respectfully submitted,



Michael D. Braun
KUZYK LAW, LLP
1999 Avenue of the Stars, Ste. 1100
Los Angeles, California 90067
Telephone: (213) 401-4100
Facsimile: (213) 401-0311
Email: mdb@kuzykclassactions.com

Counsel for Plaintiff